Posted by Michael Wonder on 26 Dec 2024
FDA approves first generic of once daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes
23 December 2024 - Today, the US FDA approved the first generic referencing Victoza (liraglutide injection) 18 mcg/3 mL, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults and paediatric patients aged 10 years and older with type 2 diabetes as an adjunct to diet and exercise.
The FDA approved the first generic in this class of medications last month with the approval of a generic referencing Byetta (exenatide).
